¡Gracias por escuchar! En este episodio se discuten las nuevas estrategias terapéuticas para el manejo del Lupus Eritematoso Sistémico. Agradezco su retroalimentación y les pido amablemente que califiquen el episodio en iTunes y en Spotify. No olviden dejar sus comentarios y sugerencias en tukua.podbean.com. 

Abajo enlisto las referencias bibliográficas consultadas en este episodio:

 

Piga, M. et al. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Arthritis. Res. Ther. 19, 247 (2017).

 

Nossent, J. et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 19, 949–956 (2010).

 

Iaccarino, L. et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J. Autoimmun. 86, 1–8 (2018).

 

Calixto, O. J., Franco, J. S. & Anaya, J. M. Lupus mimickers. Autoimmun. Rev. 13, 865–872 (2014).

 

Doria, A. & Briani, C. Lupus: improving long-term prognosis. Lupus 17, (166–170 (2008).

 

Bizzarro, N. et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study.J. Thromb. Haemost. 5, 1158–1164 (2007).

 

Pengo, V. et al. Efficacy and safety of rivaroxaban versus warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus 25, 301–306 (2016).

 

Arnaud, L. et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun. Rev. 14, 192–200 (2015).

 

Ruiz-Irastorza, G. et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th international congress on antiphospholipid antibodies. Lupus 20, 206–218 (2011).

 

Moroni, G. et al. Changing patterns in clinical- histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann. Rheum. Dis. 77, 1318–1325 (2018).

 

van Vollenhoven, R. et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann. Rheum. Dis. 76, 554–561 (2017).

 

Bertsias, G. et al. Joint European League Against Rheumatism and European Renal Association- European Dialysis and Transplant Association (EULAR/ ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann. Rheum. Dis. 71, 1771–1782 (2012).

 

Bruce, I. N. et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann. Rheum. Dis. 74, 1706–1713 (2015).

 

Al Sawah, S. et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. Lupus. Sci. Med. 2, e000066 (2015).

 

Guiducci, C. et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465, 937–941 (2010).

 

Fischer-Betz, R. et al. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study. J. Rheumatol. 39, 2111–2117 (2012).

 

Merrill, J. T. et al. Lupus community panel proposals for optimising clinical trials: 2018. Lupus. Sci. Med. 5, e000258 (2018).

 

Iaccarino, L. et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 69, 115–123 (